Astrazeneca & Bristol-myers Squibb

24-Week Phase 3 Study Found Investigational Drug Dapagliflozin Improved Glycosylated Hemoglobin (HbA1c) When Added to Glimepiride in Adults With Type 2 Diabetes Mellitus

Older News

STOCKHOLM, September 20, 2010 - Bristol-Myers Squibb Company (NYSE: BMY)(www.bms.com) and AstraZeneca (NYSE: AZN)(www.astrazeneca-us.com) today announced results from a randomized, double blind Phase 3 clinical study, which demonstrated that the addition of the investigational drug dapagliflozin to existing glimepiride (sulphonylurea) therapy produced significant reductions in glycosylated hemoglobin levels (HbA1c) in adult patients with type 2 diabetes compared to glimepiride alone.

MORE..

Corporate
|
Products
|
About Me
|
Contact
|
Privacy Policy